Today's Rundown Featured Story | | | Wednesday, February 26, 2020 Takeda has exercised its option to buy PvP Biologics, adding another celiac disease candidate to its clinical pipeline. The Japanese drugmaker pulled the trigger on the deal after getting a look at phase 1 data on the glutenase TAK-062. |
|
|---|
|
|  | Download a recent study highlighting the root of key challenges clinical operations professionals are struggling with to complete their oversight responsibilities and the important solutions this study reveals. Read Now >> |
Top Stories Wednesday, February 26, 2020 Immuno-oncology biotech Iovance Biotherapeutics’ shares rocketed up by nearly 40% Tuesday on buyout chatter. Wednesday, February 26, 2020 MPM Capital and Dana-Farber Cancer Institute have formed a venture philanthropy alliance, raising a $100 million investment fund and $26 million in donations to support early stage research. Wednesday, February 26, 2020 Vanda Pharmaceuticals is hoping to try again with an amended trial after its experimental skin drug tradipitant failed a phase 3 test. Wednesday, February 26, 2020 Tango Therapeutics is ditching its digs in Kendall Square to move into a new building in Boston’s Fenway neighborhood. One of its backers, Third Rock Ventures, is coming, too. The duo will be the first tenants of a 14-story building housing about 500,000 square feet of office and lab space Tuesday, February 25, 2020 Johnson & Johnson launched a new, virtual clinical study to gauge whether Apple’s iPhone and ECG-enabled smartwatch can help reduce a person’s risk of stroke and detect earlier, hidden cases of atrial fibrillation. Resources Sponsored by: Eagle Productivity Solutions Mediocre adoption rates aren’t due to poorly designed software or lazy users. They’re the result of how skills are trained. Achieve high adoption rates by implementing the right methodology with a focus on behavior change. Sponsored by: The Kinetix Group Read about the innovative ways payers are making smart moves in the healthcare game. Sponsored by: Veeva Learn how data management teams at ICON, Bioforum, and Vertex Pharmaceuticals are creating the spec and casebook in a single step, reducing study build times and effort by over 50%. Sponsored by: H1 Biopharma companies don't want to go to market with a product no one knows about. H1 has homed in on the often time-consuming research and engagement phases that companies must ace for a successful launch, said Ariel Katz, co-founder of H1. Sponsored by: Research Solutions / Reprints Desk Inc. 3 ways you may be overspending on scientific literature access, and how to fix them. Sponsored by: Clinical Ink Download this free white paper to learn how a BYOD ePRO approach is beneficial to your trial. Sponsored by: Catalent This whitepaper discusses the benefits of end-to-end solutions and share case studies on how flexible manufacturing strategies can accommodate the changing landscape of pharmaceutical products and help bring a drug to market. Sponsored by: Accenture Kevin Julian, senior managing director of Accenture’s life sciences practice, recently sat down with FierceBiotech to discuss market trends and Accenture’s new technology platform, INTIENT. Sponsored by: Blue Matter Consulting White paper describing how a biopharma company can successfully differentiate an oncology product when the clinical profile alone is not enough to get the job done. Sponsored by: Medidata To conduct a successful trial, do you need to understand the global eConsent Regulatory landscape? Sponsored by: Catalent Get expert insights on strategies to implement flexible manufacturing and different technologies that are easily scalable and reproducible. Sponsored by: Catalent Regardless of the assigned FDA expedited approval designation and approach, the key action items should be: the assurance of a detail-oriented plan and the adaption of a “forward-thinking” approach that will assist in any future challenges and opportunities for growth of each project. Sponsored by: Catalent Learn how recent innovations in demand-led supply and direct-to-patient distribution are converging to create a next-generation clinical supply chain that is flexible, lean and most importantly patient-centric. Sponsored by: Altran This whitepaper highlights the challenges of implementing the right digital twin strategy while providing key use cases in the manufacturing domain for which a digital twin is extremely useful and several examples of technology trends that will shape the future. Sponsored by: Catalent Pharma Solutions In this Q&A, four Catalent Biologics experts share how scale-up, regulatory expectations, demand forecasting and process validation all play a role in the success of a biologic when embarking upon the commercial manufacturing journey. | 
